Kornimate/medical-research-clean huggingface dataset:
distal clavicle resection with rotator cuff repair

Conditions: Acromioclavicular Joint Arthritis

Summary: the purpose of this study is to determine whether distal clavicle resection is effective treatments in patients with acromioclavicular joint pain accompanied by rotator cuff tear.

today, acromioclavicular joint syndrome is itself rarely a cause for hospital visit, and the need for its treatment is even rarer. in comparison, patients who suffer rotator cuff tear accompanied by shoulder impingement syndrome often complain of acromioclavicular joint pain. however, often patients who complain of severe pain have no positive findings on x-ray or mri, or any sign of impingement. on the other hand, there are patients with positive findings on x-ray or mri who have only little pain. even a patient who in the out-patient-department complained of acromioclavicular joint pain on pressure may feel pain on pressure in the physical exam performed for rotator cuff tear surgery. the opposite is very frequent as well, so it is often different depending on the time and the performer. in the literature, there are some authors who maintain that a distal clavicular resection must be done when surgery is used to treat the impingement syndrome, while on the other hand, there are those who endorse only complaining (an operation to trim the distal clavicle and the protruding part of adjust the plane acromion in order to level their plane), and also those who propose an all or none approach to either perform a distal clavicular resection or not at all. thus, there are varying opinions depending on the authors; moreover, these are all observational studies, and none report on the rotator cuff tear injury. the authors of this study hypothesize and will prove that since the osteoarthritic change and pain of the acromioclavicular joint is secondary to impingement syndrome, distal clavicular resection on rotator cuff repair surgery will have no long term effect.

Eligibility criteria:
inclusion criteria: * rotator-cuff tear requiring repair * acromioclavicular joint tenderness more than moderate(pain visual analogue scale 4-7) * acromioclavicular arthritis(petersson grade ii-iii) exclusion criteria: * arthritic changes of glenohumeral joint * combined infection * mini-open, open procedures * complete subscapularis tear * incomplete repair * neurologic abnormality including axillary nerve * adhesive capsulitis * prior surgery, trauma, or infection on shoulder girdle * slap lesion or biceps tendon lesion without rotator-cuff tear or impingement syndrome

Keywords: acromioclavicular joint arthritis distal clavicle resection mumford procedure
characterising transmission of sars-cov-2 in a peri-urban population in mozambique

Conditions: COVID-19

Summary: a population-based covid19 surveillance in a household cohort will be set-up using an existing household demographic surveillance system (hdss). from any individual in this population with any respiratory symptom or loss of smell or taste, with or without fever, investigators will collect a respiratory specimen and test these for sars-cov-2 virus, during 12 months. demographic, epidemiological and clinical data of possible cases and of the source population will be recorded at baseline. an age-stratified serial sero-survey will be conducted at baseline in a subset of the population in the population-based covid19 surveillance, and at 3, 6 and 12 months, after confirmation of community transmission.

the investigators will use the established hdss to set up population-based covid19 surveillance in a household cohort. from any individual in this population with any respiratory symptom or loss of smell or taste, with or without fever, investigators will collect a respiratory specimen and test these for sars-cov-2 virus by pcr, during 12 months. these cases will be identified through bi-weekly household visits, through an alert system involving community leaders and hdss interviewers, or when presenting with symptoms at healthcare centres or the referral hospital. demographic, epidemiological and clinical data (comorbidities, medication, obesity, hiv, tb, smoking) of possible cases and of the source population will be recorded at baseline; recent illness, potential risk exposure of each household member (including duration and type) to sars-cov-2 positive individuals, uptake of measures to reduce exposure/transmission, and barriers to the uptake of such measures, will be recorded/updated during every household visit. an age-stratified serial sero-survey will be conducted at baseline in a subset of the population in the population-based covid19 surveillance, and at 3, 6 and 12 months, after confirmation of community transmission.

Eligibility criteria:
inclusion criteria: * any individual enrolled in the polana caniço-hdss: all members residing in the household for at least 3 months (infants, children, adults, elderly), regardless of age, underlying conditions, medical history, infection or disease status or history * able and willing to provide written informed consent: by the household head for the surveillance; by each selected participant for the sero-survey. no exclusion criteria
evaluation of adhesion properties in wound care devices

Conditions: Adhesion Properties of Wound Care Devices

Summary: molnlycke manufactures and markets self-adhesive wound care devices intended to protect various types of wounds during treatment. this study aims to measure and evaluate the adhesion properties of self-adhesive wound care devices. to measure the adhesion properties test strips will be applied to the participant's skin for a predetermined time and will be removed while measuring the adhesion properties afterwards. this method has been chosen since there is no in vitro method available that can simulate adhesion to human skin


Eligibility criteria:
inclusion criteria: * confirmed eligibility and signed consent form. exclusion criteria: * known plaster allergy or other known contact hypersensitivity * pregnant or breastfeeding individual.
genome-wide study for disease susceptibility gene(s) in patients with hand osteoarthritis

Conditions: Hand Osteoarthritis

Summary: this is a case-control study involving one medical center and one research institute to develop a data-set containing a minimum of 100 osteoarthritis cases, minimum of 100 independent controls of similar gender ratio and a minimum of 100 disease controls (cases with hip and/or knee oa) to associate dna sequence (allelic) variations in candidate genes with osteoarthritis phenotypes. this study is intended to begin at the institute of biomedical sciences at academia sinica (which includes national genotyping center (ngc) and national clinical core (ncc)), national taiwan university hospital.


Eligibility criteria:
exclusion criteria: 1. patients with the following diseases will be excluded：rheumatoid arthritis, gout arthritis, psoriatic arthropathy, hypertrophic osteoarthropathy, hypermotility syndrome, hemochromatosis, post-traumatic oa, other secondary-form oa and lupus. 2. the individual is excluded if the hand x-rays show mcp changes compatible with hemochromatosis. the site then is obligated to measure fasting transferrin saturation (fe/tibc ratio) and if \>55%, the individual is excluded. 3. have more than 3 swollen mcp joints equal to, or greater than kl grade 2. 4. be unable to give informed consent. 5. one cannot participate in this study if other members of his or her immediate family have already been recruited (only one person from each family can participate in the study).
the effect of two different types of forces on possible root resorption in relation to dentin phosphoprotein levels

Conditions: Root Resorption

Summary: external root resorption is a common unfavourable sequel of orthodontic treatment. although diagnosis of root resorption is usually done by radiographs; they are technique sensitive. dentine phosphoprotein, a non-collagenous protein, is suggested to be released into the gingival crevicular fluid during active root resorption, serving as a good diagnostic tool. also, the manner of force application is a modifiable factor suggested to affect root resorption.

early detection of teeth at risk of severe resorption is crucial.at present, using radiographs is common but detecting only resorption after 60-70% of the mineralized tissue is already lost. moreover, they only provide two-dimensional information, identifying apical change primarily. also, radiographs cannot indicate if the process of root resorption is still active for monitoring its progress and additional radiation exposure to the patient will be needed. therefore, a safer, more reliable alternative method to clinically diagnose early stages of root resorption is needed and may include detecting biomarkers in gingival crevicular fluid. furthermore, the relationship between the manner of orthodontic force application and orthodontically induced root resorption is under study. it has been suggested that pausing orthodontic forces during treatment may reduce the amount of root resorption, likely due to cementum repair during the inactive period. this is important specifically in individuals who are biologically and genetically prone to root resorption. the aim of the study is to compare the extent of root resorption between controlled continuous and intermittent orthodontic forces using levels of dentin phosphoprotein in gingival crevicular fluid.

Eligibility criteria:
inclusion criteria: * malocclusion that requires extraction of first maxillary premolars on both sides. * no previous reported or observed dental treatment to the teeth to be extracted. * no previous reported or observed trauma to the teeth to be extracted. * no previous reported or observed orthodontic treatment involving the teeth to be extracted. * free of any systemic disease affecting the dentition. exclusion criteria: * past or present signs or symptoms of periodontal disease. * past or present signs or symptoms of bruxism.

Keywords: root resorption gingival crevicular fluid dentin phosphoprotein continuous force intermittent force
restorative yoga for stress management

Conditions: Stress; Anxiety

Summary: the study examined restorative yoga as a method of stress reduction for the hfa addiction medicine clinic staff volunteers.

the purpose of this study is to determine if there is a perceived benefit from adding a restorative yoga class as a method of stress reduction for the hfa addiction medicine clinic staff. working in a busy clinic can be very stressful. while it is not always possible to completely eliminate stress from our lives, it is known that stress reduction techniques help to diminish the negative consequences of stress. this study was designed to answer the following question "how much change in perceived stress is obtained through weekly restorative yoga sessions?" study population were members of the hfa addiction medicine clinic. all staff completed the spielberger job stress survey and the state-trait anxiety inventory at baseline and at six months following intervention onset. volunteers from the addiction medicine clinic attended weekly restorative yoga sessions 45 minutes in length held over the noon hour. serial state-trait anxiety inventory and weekly questionnaire regarding the perceived effects of the restorative yoga on aspects fo patient care were completed by study volunteers.

Eligibility criteria:
inclusion criteria: * member of hfa addiction medicine clinic staff * willing to participate in the restorative yoga sessions and to complete study instruments exclusion criteria: * unwilling to participate in the restorative ygoa sessions (assigned then to the control group)

Keywords: stress yoga
ixo (irinotecan, xeloda, oxaliplatin) in rectal cancer

Conditions: Rectal Cancer

Summary: this is a prospective open label single-arm, single-institution phase ii clinical trial to test the efficacy of neoadjuvant treatment with ixo (irinotecan, capecitabine \[xeloda\], oxaliplatin) followed by chemoradiotherapy and resection in patients with resectable non-metastatic primary rectal cancer of stage ct3-t4 n0-n2.


Eligibility criteria:
inclusion criteria: general * pathologically confirmed rectal adenocarcinoma * t3 or t4 or n1 (node ≥1 cm on short axis) adenocarcinoma of the rectum. * ecog performance status equal or less than 1 * male and female patients, aged ≥ 18 years and ≤ 80 years * written informed consent * adequate haematological, liver, renal function resectability * patients categorized as having resectable locally advanced cancer * favorable general condition exclusion criteria: resectability * diagnosis of metastatic disease * clear indication of involvement of pelvic wall(s), on imaging. * peritoneal carcinomatosis, portal vein occlusion, ascites, non-regional lymph nodes * histology other than adenocarcinoma * obstructed rectal carcinoma without defunctionalizing colostomy prior treatment * previously undergone treatment for this disease * prior chemotherapy for colorectal cancer * prior chemotherapy for other malignancies in past 12 months * prior radiotherapy other than skin cancer * concomitant use of st john's wort * treatment with any other investigational agent * current use of full-dose of warfarin for therapeutic other conditions * confirmed or suspected brain metastases * history or evidence of cns disease * past or current history of other malignancies * clinically significant cardiovascular disease * evidence of bleeding diathesis or coagulopathy * known hypersensitivity to any of the study drugs * serious, non-healing wound, ulcer or bone fracture * major surgical procedure or significant traumatic injury within 28 days prior to treatment * disease or condition that contraindicates the use of an investigational drug * life expectancy less than 5 years * inability or unwillingness to comply with the protocol * neuropathy ≥ gr.2 * history of ulcerative colitis or crohn's disease * pelvic abscess or perforated pelvic carcinoma pregnancy / contraception * pregnancy or lactation * positive serum pregnancy test within 7 days of starting study treatment

Keywords: locally resectable advanced adenocarcinoma of the rectum
cpr audiovisual tool to impact icu patients' surrogate anxiety level.

Conditions: Critical Illness

Summary: video or no video to decrease hcpoa/lar anxiety and increase knowledge as it pertains to cpr.

designated surrogate decision makers of 30 medical intensive care unit patients will be consented and enrolled to receive either a video describing cpr and it's outcomes after standard of care code discussions versus standard of care code discussions alone. all participants will complete a short questionnaire to determine their knowledge level regarding cpr and to assess their anxiety levels. patients who view the video will also rate their comfort level while watching the video on a 5 point likert scale.

Eligibility criteria:
surrogate decision maker or power of attorney identified within the first 48 hours of icu admission. surrogates or power of attorney over the age of 18 y/o secondary subjects: * admitted to the icu * critically ill to the point of treating team discussing code status with lar/poa/family
pet and/or mri scans in assessing tumor response in patients receiving antiangiogenesis therapy

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: diagnostic procedures, such as pet and mri scans, may help to measure a patient's response to treatment. purpose: this diagnostic trial is studying how well pet and/or mri scans work in assessing changes in tumor blood supply in patients receiving antiangiogenesis therapy.

objectives: * evaluate the ability of positron emission tomography (pet) to assess the effect of therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume in patients enrolled on a treatment protocol evaluating a therapeutic modality effecting the tumor associated vasculature. * evaluate the ability of pet to assess the effects of this type of therapy regimen on tumor uptake of fluorodeoxyglucose in these patients. * evaluate the ability of magnetic resonance imaging (mri) to assess the effects of therapy directed against the tumor vasculature on tumor blood flow and tumor vascular density in these patients. * compare the findings on pet and/or mri with those obtained from conventional ct in this patient population. outline: this is a diagnostic study conducted concurrently with a therapeutic modality study. patients have magnetic resonance imaging and/or positron emission tomography (pet) scans performed prior to start of therapy, 6 weeks and 16 weeks following the initiation of therapy, and 6 weeks following the completion of therapy. each scan requires about 1-3 hours. patients receive up to 3 different pet scans including tumor blood flow scan with h2015, tumor blood volume scan with 11co, and glucose uptake scan with fludeoxyglucose f 18. projected accrual: a total of 145 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * eligible for a treatment protocol evaluating a therapeutic modality that may have an effect on tumor associated vasculature * measurable or evaluable disease by standard ct or mri * at least 1 lesion measuring greater than 2 cm in diameter patient characteristics: age: * over 18 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * creatinine no greater than 2.0 mg/dl other: * not pregnant or nursing * negative pregnancy test * no pacemakers, aneurysm clips, shrapnel injury, or implantable electronic devices * weight no greater than 136 kilograms * no sensitivity to contrast agents that cannot be controlled with premedication prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: unspecified adult solid tumor, protocol specific
intranasal recombinant flagellin subunit campylobacter vaccine (rfla-mbp) dose-ranging study

Conditions: Diarrhea

Summary: this study is an open-labeled dose escalating trial in which a total of 32 subjects will receive one of four intranasal rfla-mbp vaccine doses.

this is an open labeled dose escalating trial in which a total of 32 subjects will receive one of four intranasal rfla-mbp vaccine doses according to the following chart: group / n\* / rfla-mbp a / 8/ 25 micrograms b / 8/ 125 micrograms c / 8/ 625 micrograms d / 8/ 1000 micrograms \* minimum of 6 volunteers per group an interval no less than 60 days following the first dose will separate the first dose of each volunteer group receiving different rfla-mbp doses. all volunteers will receive three immunizations. the first dosing time point is day 0, the second is day 14 (+/- 1 day), the third is day 28 (+/- 2 days). blood and stool specimens will be collected at intervals to examine systemic and mucosal vaccine antigen-specific immune responses. vaccine safety will be actively monitored during vaccination and for 28 days following the third vaccine dose.

Eligibility criteria:
inclusion criteria: * healthy adult * 70% accuracy on comprehension test * availability for required visits and telephone follow up exclusion criteria: * pregnancy or breastfeeding * chronic health problems * abnormalities found on physical examination * use of immunosuppressive drugs, such as corticosteroids or chemotherapy * positive blood test for hiv-1, hepatits b surface antigen (hbsag) or hepatitis c virus (hcv) * abnormalities found on basic laboratory screening * prior exposure to campylobacter * current smoker * chronic sinusitis or seasonal rhinitis

Keywords: campylobacter bacterial enteritis
prehospital resuscitation on helicopter study

Conditions: Traumatic Injuries

Summary: the prehospital resuscitation on helicopter study (prohs) is a pragmatic, multicenter, prospective observational study of air ambulance-based prehospital resuscitation regimens currently utilized at the participating sites. patients will be enrolled at participating sites that currently have blood products available on air ambulances and other sites that do not. this study will not change the current prehospital standard of care for resuscitation. the primary outcome will be in-hospital mortality and the primary unit of analysis will be the patient. other outcomes of interest will include time to hemostasis, hospital length-of-stay, number of ventilator-free and icu-free days, incidence of major surgical procedures, complications (transfusion-related acute lung injury \[trali\], acute kidney injury \[aki\], multiple organ failure \[mof\], acute respiratory distress syndrome \[ards\], sepsis, intra-abdominal complications, thromboembolic complications, compartment syndromes), lifesaving interventions, the amount and type of blood products and concentrates transfused (including prehospital), wastage of prehospital blood products and concentrates, use of external and internal hemostatic devices, and functional status at discharge/discharge destination.

all patients arriving to the participating center's trauma emergency department via helicopter directly from the scene will be screened and initial data collected. of that group, all patients who meet the "highest risk" category (based on vital signs, type of injury, use of tourniquet, and/or intubation) or received blood during transport will be followed through "direct observation" through the initial resuscitation period and then indirectly through medical chart review until hospital discharge or 30 days after admission (whichever occurs first).

Eligibility criteria:
inclusion criteria: criteria for "at risk" population * patients with traumatic injuries received directly from the scene via air ambulance service (did not receive a lifesaving intervention at an outside hospital or healthcare facility) * estimated age of 15 or older or greater than/equal to a weight of 50 kg, if age unknown criteria for "highest risk" population * meet at least one of the following during prehospital care: hr \>120 bpm, sbp ≤90 mmhg, penetrating truncal injury, tourniquet application, pelvic binder application or intubation. * received blood products during transport (for those facilities with blood product availability) exclusion criteria: * prisoners (defined as those received directly from a correctional facility.

Keywords: pre-hospital resuscitation, helicopter, trauma
treatment of good prognosis, bcl-6 negative diffuse large cell lymphoma with chop-r in patients < 61 years old.

Conditions: Non-Hodgkin Lymphoma

Summary: the purpose of this study is to determine whether a specific subtype of lymphoma responds optimally to treatment with rituximab and chemotherapy.

treatment with rituximab and chemotherapy (r-chop)is the accepted treatment for young patients with diffuse large b cell non-hodgkin's lymphoma. however not every patient benefits with this expensive therapy. recent data suggest that patients with bcl-6 negative lymphoma are more sensitive to rituximab therapy. it is also known that patients with high-intermediate and high ipi risk does not benefit form standard three weekly chop chemotherapy. in this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit. we will prospectively treat a group of patients with the following characteristics: \< 60 years old low and low intermediate ipi risk bcl-6 negative b-cell nhl treatment regimen: r-chop (standard dosis) for 8 cycles

Eligibility criteria:
inclusion criteria: * diagnosis of large b cell non-hodgkin lymphoma cd20+ * bcl-6 negative * age \< 61 years old * ecog 2 or less * ipi low, low intermediate * stage ii, iii or iv * signed informed consent exclusion criteria: * stage i * previous treatment * lymphomatous central nervous system involvement * heart disease * kidney failure (serum creatinine \> 2 mg/dl) * hiv + * viral hepatitis * pregnancy

Keywords: non-hodgkin lymphoma rituximab immunotherapy